Augmented antitumor effects of combination therapy with interleukin-12, cisplatin, and tumor necrosis factor-α in a murine melanoma model

Radosław Zagozdzon, Tomasz Stokłosa, Jakub Gołab, Adam Giermasz, Anna Dabrowska, Witold Lasek, Marek Jakóbisiak

Research output: Contribution to journalArticle

18 Citations (Scopus)

Abstract

Interleukin-12 (IL-12) has demonstrated antitumor activity in many murine tumor models. However, toxic effects resulting from treatment with IL-12 have been also described. Combining IL-12 with other antineoplastic agents could potentiate its antitumor efficacy and, furthermore, could minimize its toxicity by reducing the doses necessary to achieve the antitumor activity. We examined in a murine melanoma model the efficacy of combination tumor chemo-immunotherapy based on administration of IL-12, cisplatin (CDDP), and tumor necrosis factor-α (TNF-α). In the current study pairs of IL-12 + CDDP and IL-12 + TNF-α, showed stronger antitumor activity than either agent given alone. Furthermore, combination tumor therapy with IL-12 + CDDP + TNF-α was more effective at retarding local tumor growth than either IL-12 + CDDP, IL-12 + TNF-α or CDDP + TNF-α combination therapies. Our observations indicate that combining of CDDP with IL-12 and IL-12 with TNF-α as well as using the triple combination of CDDP, IL-12 and TNF-α could be beneficial in tumor therapy.

Original languageEnglish (US)
Pages (from-to)4493-4498
Number of pages6
JournalAnticancer Research
Volume17
Issue number6 D
StatePublished - Nov 1997
Externally publishedYes

Fingerprint

Interleukin-12
Cisplatin
Melanoma
Tumor Necrosis Factor-alpha
Therapeutics
Neoplasms
Poisons
Antineoplastic Agents
Immunotherapy

Keywords

  • Cisplatin
  • Interleukin-12
  • Melanoma
  • Mice
  • Tumor necrosis factor

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Zagozdzon, R., Stokłosa, T., Gołab, J., Giermasz, A., Dabrowska, A., Lasek, W., & Jakóbisiak, M. (1997). Augmented antitumor effects of combination therapy with interleukin-12, cisplatin, and tumor necrosis factor-α in a murine melanoma model. Anticancer Research, 17(6 D), 4493-4498.

Augmented antitumor effects of combination therapy with interleukin-12, cisplatin, and tumor necrosis factor-α in a murine melanoma model. / Zagozdzon, Radosław; Stokłosa, Tomasz; Gołab, Jakub; Giermasz, Adam; Dabrowska, Anna; Lasek, Witold; Jakóbisiak, Marek.

In: Anticancer Research, Vol. 17, No. 6 D, 11.1997, p. 4493-4498.

Research output: Contribution to journalArticle

Zagozdzon, R, Stokłosa, T, Gołab, J, Giermasz, A, Dabrowska, A, Lasek, W & Jakóbisiak, M 1997, 'Augmented antitumor effects of combination therapy with interleukin-12, cisplatin, and tumor necrosis factor-α in a murine melanoma model', Anticancer Research, vol. 17, no. 6 D, pp. 4493-4498.
Zagozdzon, Radosław ; Stokłosa, Tomasz ; Gołab, Jakub ; Giermasz, Adam ; Dabrowska, Anna ; Lasek, Witold ; Jakóbisiak, Marek. / Augmented antitumor effects of combination therapy with interleukin-12, cisplatin, and tumor necrosis factor-α in a murine melanoma model. In: Anticancer Research. 1997 ; Vol. 17, No. 6 D. pp. 4493-4498.
@article{bdb48bd370b349a2b49b8aa7abeab60b,
title = "Augmented antitumor effects of combination therapy with interleukin-12, cisplatin, and tumor necrosis factor-α in a murine melanoma model",
abstract = "Interleukin-12 (IL-12) has demonstrated antitumor activity in many murine tumor models. However, toxic effects resulting from treatment with IL-12 have been also described. Combining IL-12 with other antineoplastic agents could potentiate its antitumor efficacy and, furthermore, could minimize its toxicity by reducing the doses necessary to achieve the antitumor activity. We examined in a murine melanoma model the efficacy of combination tumor chemo-immunotherapy based on administration of IL-12, cisplatin (CDDP), and tumor necrosis factor-α (TNF-α). In the current study pairs of IL-12 + CDDP and IL-12 + TNF-α, showed stronger antitumor activity than either agent given alone. Furthermore, combination tumor therapy with IL-12 + CDDP + TNF-α was more effective at retarding local tumor growth than either IL-12 + CDDP, IL-12 + TNF-α or CDDP + TNF-α combination therapies. Our observations indicate that combining of CDDP with IL-12 and IL-12 with TNF-α as well as using the triple combination of CDDP, IL-12 and TNF-α could be beneficial in tumor therapy.",
keywords = "Cisplatin, Interleukin-12, Melanoma, Mice, Tumor necrosis factor",
author = "Radosław Zagozdzon and Tomasz Stokłosa and Jakub Gołab and Adam Giermasz and Anna Dabrowska and Witold Lasek and Marek Jak{\'o}bisiak",
year = "1997",
month = "11",
language = "English (US)",
volume = "17",
pages = "4493--4498",
journal = "Anticancer Research",
issn = "0250-7005",
publisher = "International Institute of Anticancer Research",
number = "6 D",

}

TY - JOUR

T1 - Augmented antitumor effects of combination therapy with interleukin-12, cisplatin, and tumor necrosis factor-α in a murine melanoma model

AU - Zagozdzon, Radosław

AU - Stokłosa, Tomasz

AU - Gołab, Jakub

AU - Giermasz, Adam

AU - Dabrowska, Anna

AU - Lasek, Witold

AU - Jakóbisiak, Marek

PY - 1997/11

Y1 - 1997/11

N2 - Interleukin-12 (IL-12) has demonstrated antitumor activity in many murine tumor models. However, toxic effects resulting from treatment with IL-12 have been also described. Combining IL-12 with other antineoplastic agents could potentiate its antitumor efficacy and, furthermore, could minimize its toxicity by reducing the doses necessary to achieve the antitumor activity. We examined in a murine melanoma model the efficacy of combination tumor chemo-immunotherapy based on administration of IL-12, cisplatin (CDDP), and tumor necrosis factor-α (TNF-α). In the current study pairs of IL-12 + CDDP and IL-12 + TNF-α, showed stronger antitumor activity than either agent given alone. Furthermore, combination tumor therapy with IL-12 + CDDP + TNF-α was more effective at retarding local tumor growth than either IL-12 + CDDP, IL-12 + TNF-α or CDDP + TNF-α combination therapies. Our observations indicate that combining of CDDP with IL-12 and IL-12 with TNF-α as well as using the triple combination of CDDP, IL-12 and TNF-α could be beneficial in tumor therapy.

AB - Interleukin-12 (IL-12) has demonstrated antitumor activity in many murine tumor models. However, toxic effects resulting from treatment with IL-12 have been also described. Combining IL-12 with other antineoplastic agents could potentiate its antitumor efficacy and, furthermore, could minimize its toxicity by reducing the doses necessary to achieve the antitumor activity. We examined in a murine melanoma model the efficacy of combination tumor chemo-immunotherapy based on administration of IL-12, cisplatin (CDDP), and tumor necrosis factor-α (TNF-α). In the current study pairs of IL-12 + CDDP and IL-12 + TNF-α, showed stronger antitumor activity than either agent given alone. Furthermore, combination tumor therapy with IL-12 + CDDP + TNF-α was more effective at retarding local tumor growth than either IL-12 + CDDP, IL-12 + TNF-α or CDDP + TNF-α combination therapies. Our observations indicate that combining of CDDP with IL-12 and IL-12 with TNF-α as well as using the triple combination of CDDP, IL-12 and TNF-α could be beneficial in tumor therapy.

KW - Cisplatin

KW - Interleukin-12

KW - Melanoma

KW - Mice

KW - Tumor necrosis factor

UR - http://www.scopus.com/inward/record.url?scp=2642599039&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=2642599039&partnerID=8YFLogxK

M3 - Article

C2 - 9494557

AN - SCOPUS:2642599039

VL - 17

SP - 4493

EP - 4498

JO - Anticancer Research

JF - Anticancer Research

SN - 0250-7005

IS - 6 D

ER -